BCAT1 inhibition significantly impaired growth of BCR/TLR9-pathway dependent MDC DLBCL xenografts in vivo, identifying BCAT1 as a promising novel B-cell lymphoma therapeutic target. Here, BCR is linked to B-cell non-Hodgkin lymphoma.